Differences between early and late onset Alzheimer’s disease

American Journal of Neurodegenerative Diseases

Volumn 2, Issue 4, 2013, Pages 300-306

  Panegyres, Peter K ^a   Chen, Huei Yang ^a  

^a Neurodegenerative Disorders Research Pty Ltd   (Australia)

Author keywords

Alzheimer s disease; Cognitive assessments; Early onset dementia; EOAD prognosis; Late onset dementia

Indexed keywords

C REACTIVE PROTEIN; CREATININE;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BODY MASS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; RISK FACTOR; UREA NITROGEN BLOOD LEVEL;

EID: 84980053105     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Xu W, Ferrari C, Wang HX. Epidemiology of Alzheimer's Disease. Inga Zerr, ed. InTech: Understanding Alzheimer's Disease, 2013.
2. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63-75, e62.
3. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012; 8: 131-168.
4. Seltzer B, Sherwin I. A comparison of clinical features in early- and late-onset primary degenerative dementia. One entity or two? Arch Neurol 1983; 40: 143-146.
5. Balasa M, Gelpi E, Antonell A, Rey MJ, Sánchez-Valle R, Molinuevo JL, Lladó A; Neurological Tissue Bank/University of Barcelona/Hospital Clínic NTB/UB/HC Collaborative Group. Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 2011; 76: 1720-1725.
6. Nochlin D, van Belle G, Bird TD, Sumi SM. Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer's disease. Alzheimer Dis Assoc Disord 1993; 7: 212-222.
7. Yasuno F, Imamura T, Hirono N, Ishii K, Sasaki M, Ikejiri Y, Hashimoto M, Shimomura T, Yamashita H, Mori E. Age at onset and regional cerebral glucoseh metabolism in Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9: 63-67.
8. Buchman AS, Wilson RS, Bienias JL, Shah RC, Evans DA, Bennett DA. Change in body mass index and risk of incident Alzheimer disease. Neurology 2005; 65: 892-897.
9. Skoog I, Nilsson L, Persson G, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Odén A, Svanborg A. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.
10. Atkins ER, Bulsara MK, Panegyres PK. Cerebrovascular risk factors in early-onset dementia. J Neurol Neurosurg Psychiatry 2012; 83: 666-667.
11. Dik MG, Jonker C, Hack CE, Smit JH, Comijs HC, Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology 2005; 64: 1371-1377.
12. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol 2004; 61: 668-672.
13. Kamer AR, Craig RG, Dasanayake AP, Brys M, Glodzik-Sobanska L, de Leon MJ. Inflammation and Alzheimer's disease: possible role of periodontal diseases. Alzheimers Dement 2008; 4: 242-250.
14. Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis 2009; 19: 521-524.
15. O'Bryant SE, Waring SC, Hobson V, Hall JR, Moore CB, Bottiglieri T, Massman P, Diaz-Arrastia R. Decreased C-reactive protein levels in Alzheimer disease. J Geriatr Psychiatry Neurol 2010; 23: 49-53.
16. Kutyrina IM, Rudenko TE, Shvetsov M, Kushnir VV. [Risk factors of vascular complications in patients at a predialysis stage of chronic renal failure]. Ter Arkh 2006; 78: 45-50.
17. Fernandez-Andrade C. [Renal markers and predictors, and renal and cardiovascular risk factors]. Nefrologia 2002; 22 Suppl 1: 2-29.
18. Kim CD, Lee HJ, Kim DJ, Kim BS, Shin SK, Do JY, Jang MH, Park SH, Kim YS, Kim YL. High prevalence of leukoaraiosis in cerebral magnetic resonance images of patients on peritoneal dialysis. Am J Kidney Dis 2007; 50: 98-107.
19. Atkins ER, Panegyres PK. The clinical utility of gene testing for Alzheimer's disease. Neurol Int 2011; 3: e1.
20. Bendlin BB, Ries ML, Canu E, Sodhi A, Lazar M, Alexander AL, Carlsson CM, Sager MA, Asthana S, Johnson SC. White matter is altered with parental family history of Alzheimer's disease. Alzheimers Dement 2010; 6: 394-403.
21. van Duijn CM, de Knijff P, Wehnert A, De Voecht J, Bronzova JB, Havekes LM, Hofman A, Van Broeckhoven C. The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol 1995; 37: 605-610.
22. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7: 180-184.
23. Panza F, Solfrizzi V, Torres F, Mastroianni F, Colacicco AM, Basile AM, Capurso C, D'Introno A, Del Parigi A, Capurso A. Apolipoprotein E in Southern Italy: protective effect of epsilon 2 allele in early- and late-onset sporadic Alzheimer's disease. Neurosci Lett 2000; 292: 79-82.
24. van der Flier WM, Pijnenburg YA, Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE epsilon4 allele. Lancet Neurol 2011; 10: 280-288.
25. Jacobs D, Sano M, Marder K, Bell K, Bylsma F, Lafleche G, Albert M, Brandt J, Stern Y. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology 1994; 44: 1215-1220.
26. Smits LL, Pijnenburg YA, Koedam EL, van der Vlies AE, Reuling IE, Koene T, Teunissen CE, Scheltens P, van der Flier WM. Early onset Alzheimer's disease is associated with a distinct neuropsychological profile. J Alzheimers Dis 2012; 30: 101-108.
27. Frisoni GB, Testa C, Sabattoli F, Beltramello A, Soininen H, Laakso MP. Structural correlates of early and late onset Alzheimer's disease: voxel based morphometric study. J Neurol Neurosurg Psychiatry 2005; 76: 112-114.
28. Kim EJ, Cho SS, Jeong Y, Park KC, Kang SJ, Kang E, Kim SE, Lee KH, Na DL. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain 2005; 128: 1790-1801.
29. Bigio EH, Hynan LS, Sontag E, Satumtira S, White CL. Synapse loss is greater in presenile than senile onset Alzheimer disease: implications for the cognitive reserve hypothesis. Neuropathol Appl Neurobiol 2002; 28: 218-227.
30. Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer's disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol 2007; 20: 29-33.
31. Bird TD, Stranahan S, Sumi SM, Raskind M. Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups. Ann Neurol 1983; 14: 284-293.
32. Rossor MN, Iversen LL, Reynolds GP, Mountjoy CQ, Roth M. Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J (Clin Res Ed) 1984; 288: 961-964.
33. Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O'Neil JP, Janabi M, Baker SL, Agarwal N, Bonasera SJ, Mormino EC, Weiner MW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 2010; 133: 512-28.
34. Braak H, Del Tredici K. Alzheimer's disease: pathogenesis and prevention. Alzheimers Dement 2012; 8: 227-33.